https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00neilhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgneil2019-11-12 19:45:002021-09-09 15:22:38Presentation: A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2019-10-29 18:25:002021-09-09 15:22:45Press Release: Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2018-07-16 19:58:222021-09-09 15:22:52Press Release: Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin
Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200 June 11, 2018 07:58 AM Eastern Daylight Time FAIRFAX, Va.–(EON: Enhanced Online News)–Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the initiation of clinical study VZU00025: A Phase […]
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2018-06-11 07:58:232021-09-09 15:22:59Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200
Well-Tolerated Topical Capsaicin Formulation Reduces Knee OA Pain
/in references (CGS-200-5) /by neilNews coverage of our CGS-200-5 Phase 2 results for OA pain of the knee. Read Article
Presentation: A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
/in presentations /by neilView the results of our Phase 2 clinical study of CGS-200-5 presented at the 2019 ACR Annual Meeting View Abstract
Press Release: Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting
/in press releases /by altusdevsite_4grsdfVizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting
Press Release: Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin
/in press releases /by altusdevsite_4grsdfVizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin
Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200
/1 Comment/in press releases /by altusdevsite_4grsdfPress Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200 June 11, 2018 07:58 AM Eastern Daylight Time FAIRFAX, Va.–(EON: Enhanced Online News)–Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the initiation of clinical study VZU00025: A Phase […]